[Treatment of multiple sclerosis]

Tidsskr Nor Laegeforen. 2010 May 6;130(9):923; author reply 923. doi: 10.4045/tidsskr.10.0346.
[Article in Norwegian]
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Leukoencephalopathy, Progressive Multifocal / chemically induced
  • Multiple Sclerosis / drug therapy*
  • Natalizumab
  • Risk Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Natalizumab